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Abstract
Objective/Background: Acute myeloid leukemia (AML) is one of the common forms of hematological malignancy and
acute promyelocytic leukemia (APL) is a unique subtype of AML conferring favorable prognosis. We aimed to determine
the prevalence and prognostic impact of Fms-like tyrosine kinase 3 (FLT3), nucleophosmin 1 (NPM1) mutation,
epidermal growth factor receptor (EGFR), and ﬂow marker’s expression in patients with APL.
Methods: In the present study, 165 de novo APL patients were molecularly characterized for promyelocytic leukemia
(PML) breakpoint and additional genetic alterations. Reverse transcriptase polymerase chain reaction (PCR) and realtime PCR assays were used to detect genetic alterations.
Results: PML/RARa was detected in 29/165 (17.5%) samples with breakpoint cluster region 1 (bcr1) in 17/29 (58.5%) and
bcr3 in 12/29 (41.5%) samples. The prevalence of FLT3-ITD, NPM1, and EGFR were detected in 5/29 (17.5%), 11/29 (38%),
and 5/29 (17.5%) patients, respectively. Patients expressing bcr-3 hybrid transcript had lower overall survival compared
with bcr1 ( p ¼ .254). White blood cell (WBC) count was signiﬁcantly higher in bcr3 in comparison with bcr1 patients ( p
¼ .002). Patients with positive EGFR expression ( p ¼ .042) and higher WBC ( p ¼ .002) were signiﬁcantly associated with
poor survival ( p < .05).
Conclusions: We documented the higher prevalence of bcr1 and conﬁrmed that the association of FLT3-ITD signiﬁcantly reduced the chances of survival in APL. The mortality rate of bcr3 was comparatively higher than that of bcr1.
Higher WBC count and EGFR expression were signiﬁcantly associated with poor survival.
Keywords: APL, Co-prevalence, Genetic alterations, Prognosis

1. Introduction

A

lmost 92% of acute promyelocytic leukemia
(APL) cases show classical t(15;17) translocation whereas 5% shows nonclassical genetic
abnormalities. Classical translocation results in
three different transcripts: breakpoint cluster region
1 (bcr1), breakpoint cluster region 2 (bcr2), and
breakpoint cluster region 3 (bcr3). Most frequent

transcripts are bcr1 and bcr3, whereas bcr2 is rare
[1]. A higher prevalence of bcr1 over bcr3 was reported by different studies in different ethnic populations [2]. Fms-like tyrosine kinase 3 (FLT3) and
nucleophosmin 1 (NPM1) genes are the two most
common genetic alterations in acute myeloid leukemia (AML) with worse and favorable prognosis,
respectively [3]. Epidermal growth factor receptor
(EGFR) plays a signiﬁcant role in several epithelial
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cancers with high expression. The presence of EGFR
has been associated with worse outcome in AML [4].
Immunophenotyping has a diagnostic and prognostic impact on AML subtypes [5]. ATRA/ATO- (all
trans-retinoic acid/arsenic trioxide) or ATRA-based
induction therapy is the current gold standard
treatment for APL patients.
The paucity of studies from India relating to the
clinical signiﬁcance of other genetic alterations and
ﬂow markers in APL patients prompted us to carry
out this study. We are reporting the possible inﬂuence of FLT3, NPM1 mutation, EGFR, and ﬂow
marker’s expression on APL patients from a cohort
in North East India.

2. Materials and methods
2.1. Samples
Bone marrow and/or peripheral blood was
collected from 165 AML patients at the Department
of Clinical Haematology, Gauhati Medical College
& Hospital (GMCH; Assam, India) with written
informed consent (90 males and 75 females; age
range, 1e84 years).
2.2. Cytomorphology, cytogenetics, and ﬂow
cytometry
Bone marrow and peripheral blood smears were
stained as per standard techniques, including
MayeGrunwaldeGiemsa stains and myeloperoxidase following FrencheAmericaneBritish (FAB)
and World Health Organization (WHO) criteria [6].
Karyotyping was done at diagnosis according to the
International System for Human Cytogenetic
Nomenclature [7], and ﬂow cytometry was performed from peripheral blood or bone marrow
samples according to the presence and availability
of blast cells as described [8].
2.3. Molecular studies
Real-time polymerase chain reaction (PCR) was
performed for PML/RARa (promyelocytic leukemia/
retinoic acid receptor alpha; Hs03043651_ft for bcr1
and
Hs03024794_ft
for
bcr3)
and
EGFR
(Hs01076078_m1) using TaqMan inventoried assays.
FLT3 and NPM1 mutations were detected as previously described [9].
2.4. Statistical analysis
All statistical analyses were performed using statistical packages SPSS 22.0 (SPSS Inc., Chicago, IL,
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USA) and Epi Info 2000 (Centers for Disease Control
and Prevention, Atlanta, GA, USA). A two-sided p
value < 0.05 was considered statistically signiﬁcant.

3. Results
PML/RARa t(15;17) was detected in 29/165 (17.5%;
95% conﬁdence interval [CI], 12.5e24.1%) patients.
Among them, 14 patients were male (48%) and 15
patients were female (52%). Real-time PCR results
exhibited bcr1 in 17 patients 17/29 (58.5%) and bcr3
in 12 cases 12/29 (41.5%). Of 29 APL patients, 5 patients were FLT3-ITD positive (17.5%). NPM1 mutants were detected in 11 patients (38%), which was
a striking observation among APL patients, and
EGFR expression was detected in 5 patients (17.5%).
FLT3-D835 mutations were not detected in APL
patients.
Induction outcome and association of demographic, laboratory, immunophenotype, and
other clinical characteristics with survival.
The overall induction death rate in this series was
6/29 (20.7%) (Table 1). The median survival for the
patients with FLT3-ITD negative was observed to be
signiﬁcantly higher (median survival, >27 months)
compared with patients with FLT3-ITD positive
(median survival, 0.5 months; 95% CI, 0.13e0.86;
log-rank test p < .001). The induction death rate was
higher in patients with bcr3 than in patients with
bcr1 (34% vs. 12%, p ¼ .344). The overall complete
remission (CR) rate was 17/29 (58.7%), and there
was higher CR in patients with bcr1 compared with
patients with bcr3 (65% vs. 50%, p ¼ .681). The exact
median survival of PML/RARa patients could not be
reached owing to the shorter follow-up duration;
however, in bcr1 positive patients, the overall median survival was recorded as 27 months (median
survival, >27 months; mean survival, 20 months;
95% CI, 14.9e26) compared with the median survival > 26 months (mean survival, 15 months; 95%
CI, 8.2e22.7) in bcr3 positive, and the difference was
not statistically signiﬁcant (log-rank p ¼ .254). Patients with positive EGFR expression (log-rank test p
¼ .042) and higher white blood cell (WBC) count ( p
¼ .002) were signiﬁcantly associated with poor survival ( p < .05). However, mortality or death % was
insigniﬁcant between positive and negative EGFR
patients. Similarly, positive M3v, HLA-DR (human
leukocyte antigen, DR isotype), CD34, CD56, and
CD2 were associated with poor survival, but were
not statistically signiﬁcant (data not shown because
of the very small number present in each respective
group). Moreover, sex (log-rank test p ¼ .654) and
age (log-rank test p ¼ .357) did not signiﬁcantly ( p >
.05) inﬂuence overall survival (OS); however, OS
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Table 1. Association between demographic, laboratory, immunophenotype, and other clinical characteristics with bcr1 and bcr3.
Demographic, laboratory, and
clinical characteristics

Sex
Male
Female

Age (y)
WBC count, 109/L
Platelet count, 109/L
Hemoglobin level, g/dL
Blast count, %

CD34
CD56
CD2
HLA-DR
FLT3-ITD
NPM1
Hypogranular or M3v
EGFR gene expression

Early death
Complete remission

APL-speciﬁc PML/RARa (n ¼ 29)
bcr1 (n ¼ 17)
n (%)

bcr3 (n ¼ 12)
n (%)

p

9 (53)
8 (47)

5 (42)
7 (58)

0.550

bcr1
Mean ± SD [median (range)]

bcr3
Mean ± SD [median (range)]

p

24.94 ± 16.40 [20.0 (6e65)]
26.74 ± 40.69 [13.3 (9e170)]
43.31 ± 34.58 [32.7 (7e134)]
8.36 ± 1.91 [8.3 (3.3e10.7)]
39.35 ± 9.54 [39 (28e60)]

30.71 ± 16.39 [28.0 (8.5e65)]
44.07 ± 44.25 [22.4 (15.7e150)]
43.32 ± 41.12 [29.9 (8e150)]
7.54 ± 2.45 [7.5 (4e11.4)]
42.75 ± 16.0 [41.5 (25e75)]

0.359
0.002
0.626
0.321
0.842

bcr1
Positive, n (%)

bcr3
Positive, n (%)

p

0
1
1
0
2
4
1
3

2
1
0
1
3
7
2
2

0.163
0.998
0.995
0.414
0.622
0.057
0.553
0.992

(0)
(5.9)
(5.9)
(0)
(11.8)
(23.5)
(5.9)
(17.6)

(16.7)
(8.3)
(0)
(8.3)
(25)
(58.3)
(16.7)
(16.7)

bcr1
n (%)

bcr3
n (%)

p

2 (12)
11 (65)

4 (34)
6 (50)

0.344
0.681

*p-values computed using Pearson chi-square test and Fisher’s exact test, unpaired and ManneWhitney U tests.
APL ¼ acute promyelocytic leukemia; EGFR ¼ epidermal growth factor receptor; FLT3 ¼ Fms-like tyrosine kinase 3; HLA-DR ¼ human
leukocyte antigen, DR isotype; NMP1 ¼ nucleophosmin 1; PML/RARa ¼ promyelocytic leukemia/retinoic acid receptor alpha; SD ¼
standard deviation; WBC ¼ white blood cell; y, year.

was longer in younger patients (aged  20 years)
and females, respectively. Furthermore, in 2/12 patients with bcr3, additional deletion of 7q was found.
3.1. Treatment protocol and monitoring of minimal
residual disease
All APL patients were treated at the Department
of Clinical Haematology, GMCH, as per the ASH
International Committee Acute Promyelocytic
Leukaemia Protocol (IC-APL2006) [10]. In our study,
three patients (1 bcr1 patient and 2 bcr3 patients)
died because of severe bleeding before the induction therapy could be started. Minimal residual
disease was analyzed in 20 patients using real-time
PCR to conﬁrm the CR, and results revealed the
absence of PML/RARa fusion transcripts in 17 patients. Three patients were detected to be positive
after induction therapy, but they died before the
consolidation therapy could be started. Four patients discontinued the treatment and follow-up
with two patients was lost. CR was achieved after

induction and consolidation therapy for 17/29
(58.7%) of patients.

4. Discussion
We assessed the prevalence and prognostic
impact of APL patients. The associations of other
genetic alterations have also been demonstrated to
understand any possible role in disease outcome.
The incidence of PML/RARa transcripts detected in
this population was 17.5%, which is in line with
other studies in Asian and Western countries. In our
study, the prevalence of bcr1 was higher compared
with bcr3, a pattern that reﬂects earlier reports [2].
No signiﬁcant characteristic differences were
observed between bcr1 and bcr3 for age, sex, hemoglobin concentration, platelet, and blast count
except for WBC count. Patients expressing bcr3
were found to be associated with lower survival
period. One possible cause could be additional cytogenetic changes in bcr3 patients compared with
bcr1 patients [11].
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An earlier study reported the presence of FLT3-ITD
in APL with a signiﬁcantly lower OS [12]. In our study,
three patients died during the treatment period (1
bcr1 patient and 2 bcr3 patients), which can be
correlated to their association with FLT3-ITD. Swaminathan et al [13] showed that the incidence rate of
NPM1 mutations was higher (45%) in Indian APL
patients, and a similar trend (38%) was also observed
in our study, which indicates that NPM1 mutation
might be frequent in Indian APL patients. The
expression of EGFR in AML is poorly deﬁned and the
role of EGFR in AML remains contradictory [14]. Out
of 29 patients, 3 bcr1 patients and 2 bcr3 (5/29; 17.5%)
patients showed EGFR expression, which conﬁrmed
the presence of EGFR in AML. Sun et al. [4] showed
EGFR confers worse clinical outcomes in AML, and
we are in agreement with their studies. In the current
study, CD13, CD33, and CD117 were detected positive in all cases, indicating their potential use as a
therapeutic target in treatment of patients with APL in
the future. The expression of CD56 in APL patients
can be considered a poor prognostic marker [15]. In
our study, two patients with CD56 were detected and
both died, which can be correlated to their classiﬁcation under the high-risk category (WBC, >10  109/
L; platelets, 40  109/L).
In conclusion, we found higher prevalence of bcr1
over bcr3 and conﬁrm that the association of FLT3ITD signiﬁcantly reduces the chances of survival in
APL. APL patients with bcr3 variants have a short
survival period compared with those with the bcr1
variant. EGFR, CD56 expression, and higher WBC
count are signiﬁcantly associated with poor survival
in patients with APL.
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